{"nctId":"NCT00354744","briefTitle":"High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma","startDateStruct":{"date":"2006-07"},"conditions":["Sarcoma"],"count":109,"armGroups":[{"label":"High Risk Rhabdomyosarcoma","type":"EXPERIMENTAL","interventionNames":["Biological: dactinomycin","Drug: cyclophosphamide","Drug: doxorubicin hydrochloride","Drug: etoposide","Drug: ifosfamide","Drug: irinotecan hydrochloride","Drug: vincristine sulfate","Procedure: conventional surgery","Radiation: radiation therapy","Biological: filgrastim"]}],"interventions":[{"name":"dactinomycin","otherNames":["Actinomycin-D","Cosmegen","NSC #3053"]},{"name":"cyclophosphamide","otherNames":["Cytoxan","NSC #26271"]},{"name":"doxorubicin hydrochloride","otherNames":["Adriamycin","NSC #123127"]},{"name":"etoposide","otherNames":["VePesid","Etopophos","VP-16","NSC #141540"]},{"name":"ifosfamide","otherNames":["Isophosphamide","Iphosphamide","Z4942","Ifex","NSC #109724"]},{"name":"irinotecan hydrochloride","otherNames":["CPT-11","Camptothecin-11","7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin","Camptosar","NSC #616348"]},{"name":"vincristine sulfate","otherNames":["Oncovin","VCR","LCR","NSC #67574"]},{"name":"conventional surgery","otherNames":[]},{"name":"radiation therapy","otherNames":[]},{"name":"filgrastim","otherNames":["Granulocyte Colony-Stimulating Factor","r-metHuG-CSF","G-CSF","Neupogen","NSC #614629"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Histologically confirmed high-risk rhabdomyosarcoma or ectomesenchymoma\n\n  * Prior enrollment on COG-D9902 to confirm local histological diagnosis required\n\n    * Tissue must be submitted for pathologic review within 2 days of patient registration on COG-D9902\n  * Newly diagnosed disease\n  * Metastatic disease (stage IV, clinical group IV)\n* Has undergone initial surgical procedure (including biopsy) that provided the definitive diagnosis within the past 42 days\n* Parameningeal and paraspinal tumors allowed\n\n  * Patients with parameningeal (without intracranial extension \\[ICE\\]) and paraspinal tumors should begin study chemotherapy at week 1 and radiotherapy at week 20\n* Patients with evidence of ICE, as defined by contrast MRI showing that primary tumor touches, displaces, invades, distorts, or otherwise causes a signal abnormality of the dura in contiguity to the primary site in brain or spinal cord, are eligible\n\n  * ICE is presumed to exist if the cerebrospinal fluid cytopathology is positive for tumor at diagnosis\n* Patients requiring emergency radiotherapy are eligible\n\n  * Patients requiring emergency radiotherapy (for intracranial extension or spinal cord impingement) should begin study chemotherapy at week 1 (irinotecan hydrochloride and vincristine) concurrently with radiation therapy\n\nPATIENT CHARACTERISTICS:\n\n* ECOG or Zubrod performance status (PS) 0-2 (Lansky PS 50-100% for patients \\< 10 years of age and Karnofsky PS 50-100% for patients ≥ 10 years of age)\n* Absolute neutrophil count ≥ 750/mm³\\*\n* Platelet count ≥ 75,000/mm³\\*\n* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min (≥ 40 mL/min for infants \\< 1 year of age)\n* Patients with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract\n* SGPT \\< 2.5 times normal\n* Bilirubin \\< 1.5 mg/dL\n* Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 50% by MUGA\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during study and for ≥ 1 month after study completion\n* No evidence of uncontrolled infection\n* Able to undergo radiotherapy NOTE: \\*Abnormal blood counts allowed if there is bone marrow biopsy or aspirate proven bone marrow involvement by rhabdomyosarcoma\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy except steroids\n* No prior radiotherapy\n* No concurrent aprepitant during ifosfamide or doxorubicin hydrochloride chemotherapy\n* No concurrent dexrazoxane\n* No concurrent sargramostim (GM-CSF) or pegfilgrastim","healthyVolunteers":false,"sex":"ALL","maximumAge":"49 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients With Complete or Partial Response Assessed by RECIST Criteria","description":"Volumetric measurements of the primary tumor using an elliptical model (0.5 x the product of the 3 largest perpendicular diameters) to assess response to neoadjuvant therapy. The RECIST (Response Evaluation Criteria in Solid Tumors) from the NCI will be used for assessment of the size of measurable metastases, including nodal metastases. Primary Tumor Measurement: Technical guidelines for cross-sectional imaging computed tomography (CT) slice thickness should be 5mm or less and the diameter of the \"measurable\" mass should be at least twice the reconstructed slice thickness. Smaller masses are considered detectable, but will be counted as \"non-measurable.\" Complete Response (CR): Complete disappearance of the tumor confirmed at \\>4 weeks. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Progressive Disease (PD): At least 40% increase in tumor volume compared to the smallest volume obtained since the beginning.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Experiencing Adverse Events Due to Concurrent Therapy","description":"Adverse events are reported for patients receiving concurrent irinotecan hydrochloride and radiotherapy.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Event Free at 4 Years Following Study Entry","description":"Event-free survival: Time to recurrence, second malignancy, or death as a first event, estimated from a Kaplan Meier curve","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":108},"commonTop":["Infections and infestations - Other","Febrile neutropenia","Diarrhea","Anorexia","Nausea"]}}}